Cancer drug resistance: a new perspective

Peters, Godefridus J.

doi:10.20517/cdr.2018.03

Cited by 23 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatments range from only surgery, when the tumor is local, to combinations of surgery, radiation, chemotherapy, and targeted therapy depending on tumor size, metastasis, and molecular signatures [ 24 , 25 ]. Except for surgery, almost any breast cancer treatment can result in resistance and a growing body of evidence points to CSCs as the source of resistance [ 5 , 26 , 27 ]. Breast CSCs are tumorigenic multi-potential cells with deregulated self-renewal properties [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

Solvent fractions of selected Ethiopian medicinal plants used in traditional breast cancer treatment inhibit cancer stem cells in a breast cancer cell line

Tuasha

Seifu

Gadisa

et al. 2020

BMC Complement Med Ther

View full text Add to dashboard Cite

Background The incidence and mortality of breast cancer in women is increasing worldwide. Breast cancer contains a subpopulation of cells known as cancer stem cells (CSCs). The CSCs are believed to be responsible for chemotherapeutic resistance and are also involved in tumor initiation, progression, evolution, and metastasis to distant sites. The present study aimed to investigate the anti-CSC potential of selected Ethiopian medicinal plants traditionally used for breast cancer treatment. Methods The solvent fractions of three medicinal plants (the ethyl acetate fraction of Vernonia leopoldi, the aqueous fraction of Sideroxylon oxyacanthum, and the chloroform fraction of Clematis simensis) resulting from the methanolic crude extracts were selected based on their previously demonstrated cytotoxic effects on breast cancer cell lines. The effect of these solvent fractions on the status of the cancer stem cell subpopulation of the JIMT-1 cell line was assessed by flow cytometric evaluation of the proportion of aldehyde dehydrogenase positive cells and by measuring colony forming efficiency in a serum-free soft agar assay after treatment. Effects on cell migration using a wound healing assay and on tumor necrosis factor-α-induced translocation of nuclear factor-kappa B to the cell nucleus were also investigated. Results The solvent fractions showed a dose-dependent reduction in the aldehyde dehydrogenase positive subpopulation of JIMT-1 cells. The chloroform fraction of C. simensis (80 μg/mL) completely blocked colony formation of JIMT-1 cells. The wound healing assay showed that all fractions significantly reduced cell migration. The ethyl acetate fraction of V. leopoldi (0.87 μg/mL) significantly inhibited tumor necrosis factor-α-induced nuclear factor-kappa B translocation to the nucleus. Conclusion The solvent fractions of the medicinal plants showed desirable activities against breast cancer stem cells in the JIMT-1 cell line, which warrants further studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Solvent fractions of selected Ethiopian medicinal plants used in traditional breast cancer treatment inhibit cancer stem cells in a breast cancer cell line

Tuasha

Seifu

Gadisa

et al. 2020

BMC Complement Med Ther

View full text Add to dashboard Cite

show abstract

“…Recently, the recorded cases of people dying from infectious diseases are on the rise owing to antibiotic-resistant bacterial strains [1]. Similarly, cancer treatments present cellular resistances and poor selectivities, thereby generating many adverse effects that result in this disease being the second most common cause of death worldwide, mainly by lung, prostate, and breast cancer [2,3]. Additionally, the resistance and low selectivity of anticancer drugs led to an increase in the pace and scope of research aimed at developing new drugs of both types [4].…”

Section: Introductionmentioning

confidence: 99%

In Silico Selection and Evaluation of Pugnins with Antibacterial and Anticancer Activity Using Skin Transcriptome of Treefrog (Boana pugnax)

et al. 2021

View full text Add to dashboard Cite

In order to combat bacterial and cancer resistance, we identified peptides (pugnins) with dual antibacterial l–anticancer activity from the Boana pugnax (B. pugnax) skin transcriptome through in silico analysis. Pugnins A and B were selected owing to their high similarity to the DS4.3 peptide, which served as a template for their alignment to the B. pugnax transcriptome, as well as their function as part of a voltage-dependent potassium channel protein. The secondary peptide structure stability in aqueous medium was evaluated as well, and after interaction with the Escherichia coli (E. coli) membrane model using molecular dynamics. These pugnins were synthesized via solid-phase synthesis strategy and verified by Reverse phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. Subsequently, their alpha-helix structure was determined by circular dichroism, after which antibacterial tests were then performed to evaluate their antimicrobial activity. Cytotoxicity tests against cancer cells also showed selectivity of pugnin A toward breast cancer (MFC7) cells, and pugnin B toward prostate cancer (PC3) cells. Alternatively, flow cytometry revealed necrotic cell damage with a major cytotoxic effect on human keratinocytes (HaCaT) control cells. Therefore, the pugnins found in the transcriptome of B. pugnax present dual antibacterial–anticancer activity with reduced selectivity to normal eukaryotic cells.

show abstract

“…Resistance can be intrinsic or acquired when there is low or no response to anticancer therapy from the beginning or during the course of therapy, respectively. One-drug resistance refers to resistance to one specific drug; when patients show resistance to one drug and become resistant to other unrelated drugs (with different structures and mechanisms of action), the term multidrug resistance (MDR) is employed [ 5 ].…”

Section: Introduction: Limitations Of Anticancer Therapiesmentioning

confidence: 99%

Drug Delivery Systems of Natural Products in Oncology

Colone¹,

Calcabrini²,

Stringaro³

2020

Molecules

View full text Add to dashboard Cite

In recent decades, increasing interest in the use of natural products in anticancer therapy field has been observed, mainly due to unsolved drug-resistance problems. The antitumoral effect of natural compounds involving different signaling pathways and cellular mechanisms has been largely demonstrated in in vitro and in vivo studies. The encapsulation of natural products into different delivery systems may lead to a significant enhancement of their anticancer efficacy by increasing in vivo stability and bioavailability, reducing side adverse effects and improving target-specific activity. This review will focus on research studies related to nanostructured systems containing natural compounds for new drug delivery tools in anticancer therapies.

show abstract

Cancer drug resistance: a new perspective

Cited by 23 publications

References 30 publications

Solvent fractions of selected Ethiopian medicinal plants used in traditional breast cancer treatment inhibit cancer stem cells in a breast cancer cell line

Solvent fractions of selected Ethiopian medicinal plants used in traditional breast cancer treatment inhibit cancer stem cells in a breast cancer cell line

In Silico Selection and Evaluation of Pugnins with Antibacterial and Anticancer Activity Using Skin Transcriptome of Treefrog (Boana pugnax)

Drug Delivery Systems of Natural Products in Oncology

Contact Info

Product

Resources

About